Journal Watch 10/4/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
top of page
Browse by category
Search
Semaglutide and tirzepatide decrease cravings and reduce alcohol consumption
An analysis of social media posts and a remote study of individuals with obesity who reported using semaglutide and tirzepatide, has...
Semaglutide not associated with increased suicidal thoughts
Semaglutide used in the diabetes drug Ozempic and the weight-management drug Wegovy is not associated with an increased risk for suicidal...
Semaglutide associated with reductions in alcohol use disorder symptoms
Semaglutide specifically reduces the symptoms of alcohol use disorder (AUD), according to researchers at the University of Oklahoma...
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...
SELECT: Semaglutide reduces CV events in non-diabetic patients with overweight or obesity
Semaglutide 2.4mg (Wegovy) reduces cardiovascular events in patients with overweight or obesity and pre-existing cardiovascular disease...
Journal Watch 8/11/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Journal Watch 27/09/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Semaglutide medication may benefit 93 million US adults
Researchers from the University of California, Irvine, have published a study that projects 93 million US adults that are overweight and...
Semaglutide decreases cardiovascular risk score after one year of use
Two new studies presented at this year's European Congress on Obesity have revealed that semaglutide is effective for weight loss in a...
Browse by tag
bottom of page